Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma

Jun LIU; Ling WANG; Yuhuan JIANG; Jingzhi WANG; Huiming LI

doi:10.12449/JCH241218

Volume 40 Issue 12

Dec. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(12): 2473-2483

PDF( 6319 KB)

Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma

DOI: 10.12449/JCH241218

1.
Department of Clinical Laboratory，The First Affiliated Hospital of Nanchang University，Nanchang 330006，China
2.
The First Clinical Medical College of Nanchang University，Nanchang 330038，China

Research funding:

Key Projects of Jiangxi Provincial Department of Education (GJJ210135);

Jiangxi Provincial Department of Education (GJJ200147);

Jiangxi Traditional Chinese Medicine Science and Technology Plan Project (2022B966)

More Information

Corresponding author: LI Huiming， hmingl2321@163.com （ORCID： 0000-0001-8297-2724）
Received Date: 2024-04-23
Accepted Date: 2024-07-10
Published Date: 2024-12-25

Abstract

Abstract

Objective To identify immunogenic cell death （ICD）-related genes in hepatocellular carcinoma （HCC）， and to establish a scoring model based on these genes for predicting the prognosis and tumor microenvironment characteristics of HCC. Methods The Cancer Genome Atlas database was used to obtain HCC datasets， and heatmaps were used to display the expression of 57 ICD-related genes in HCC. A cluster analysis was conducted based on the expression of ICD-related genes， and two ICD subtypes （low and high ICD expression groups） were analyzed in terms of gene ontology enrichment analysis， Kyoto Encyclopedia of Genes and Genomes （KEGG） enrichment analysis， somatic mutation， and immune cell infiltration. The LASSO Cox regression risk model was constructed to evaluate its clinical application value， and a nomogram model was established to predict the 1-， 3-， and 5-year survival rates of patients. In addition， qRT-PCR was used to validate the expression levels of key genes in the model. The independent-samples t test was used for comparison between two groups， and the univariate and multivariate Cox regression analyses were used to determine prognostic factors among clinicopathological features. The Kaplan-Meier survival curve was used for prognostic analysis， and the Spearman rank correlation test was used for correlation analysis. Results The low ICD expression group had a poorer prognosis， while the high ICD expression group had relatively favorable clinical outcomes （P=0.004）. Further analysis showed that the high ICD expression group was associated with an immune-active microenvironment， and the genes were mainly enriched in immune-related pathways such as immunoglobulin receptor binding， hematopoietic cell lineage， and B cell receptor. The results of somatic mutation analysis showed that the high ICD expression group had higher expression levels of CD274， CTLA4， HAVCR2， TIGIT， PDCD1， and PDCD1LG2 （all P<0.05）. A risk prediction model was established using 8 ICD-related genes， i.e.， HSP90AA1， ATG5， BAX， PPIA， HSPA4， TLR2， TREM1， and LY96， and this model showed a good predictive value across different clinical characteristics. The univariate and multivariate Cox regression analyses showed that age and risk score were independent prognostic factors for overall survival in the training set （both P<0.05）. The results of qRT-PCR showed that the relative expression levels of HSPA4 and REM1 in HCC tumor samples were significantly higher than those in adjacent tissue samples （both P<0.001）. For the patients with an increase in ICD risk score， the ICD risk score was negatively correlated with γδT cells （r=-0.29， P<0.05）， plasma cells （r=-0.3， P<0.05）， and CD8⁺T lymphocytes （r=-0.37， P<0.05） and was positively correlated with memory B cells （r=0.38， P<0.05）， resting dendritic cells （r=0.47， P<0.05）， and M0 macrophages （r=0.49， P<0.05）. Conclusion This study identifies the ICD-related genes that are associated with the prognosis of HCC， which provides insights into the immune characteristics of different ICD expression profiles. The risk model and the nomogram model established in this study have a significant value for predicting the prognosis of HCC patients and guiding immunotherapy for HCC patients.
- Carcinoma， Hepatocellular,
- Immunogenic Cell Death,
- Prognosis,
- Tumor Microenvironment

FullText(HTML)

References(26)

References

[1]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400: 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[2]	GANESAN P, KULIK LM. Hepatocellular carcinoma: New developments[J]. Clin Liver Dis, 2023, 27( 1): 85- 102. DOI: 10.1016/j.cld.2022.08.004.
[3]	LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7( 1): 6. DOI: 10.1038/s41572-020-00240-3.
[4]	ZHANG YY, ZHANG ZM. The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications[J]. Cell Mol Immunol, 2020, 17( 8): 807- 821. DOI: 10.1038/s41423-020-0488-6.
[5]	NAIMI A, MOHAMMED RN, RAJI A, et al. Tumor immunotherapies by immune checkpoint inhibitors(ICIs); the pros and cons[J]. Cell Commun Signal, 2022, 20( 1): 44. DOI: 10.1186/s12964-022-00854-y.
[6]	KENNEDY LB, SALAMA AKS. A review of cancer immunotherapy toxicity[J]. CA Cancer J Clin, 2020, 70( 2): 86- 104. DOI: 10.3322/caac.21596.
[7]	LLOVET JM, CASTET F, HEIKENWALDER M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19( 3): 151- 172. DOI: 10.1038/s41571-021-00573-2.
[8]	SANGRO B, SAROBE P, HERVÁS-STUBBS S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 8): 525- 543. DOI: 10.1038/s41575-021-00438-0.
[9]	NIU X, CHEN LJ, LI Y, et al. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC[J]. Semin Cancer Biol, 2022, 86( Pt 3): 273- 285. DOI: 10.1016/j.semcancer.2022.03.009.
[10]	CAI JY, HU YY, YE Z, et al. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma[J]. Front Immunol, 2022, 13: 1011757. DOI: 10.3389/fimmu.2022.1011757.
[11]	KROEMER G, GALASSI C, ZITVOGEL L, et al. Immunogenic cell stress and death[J]. Nat Immunol, 2022, 23( 4): 487- 500. DOI: 10.1038/s41590-022-01132-2.
[12]	AHMED A, TAIT SWG. Targeting immunogenic cell death in cancer[J]. Mol Oncol, 2020, 14( 12): 2994- 3006. DOI: 10.1002/1878-0261.12851.
[13]	FUCIKOVA J, KEPP O, KASIKOVA L, et al. Detection of immunogenic cell death and its relevance for cancer therapy[J]. Cell Death Dis, 2020, 11( 11): 1013. DOI: 10.1038/s41419-020-03221-2.
[14]	ZHOU JY, WANG GY, CHEN YZ, et al. Immunogenic cell death in cancer therapy: Present and emerging inducers[J]. J Cell Mol Med, 2019, 23( 8): 4854- 4865. DOI: 10.1111/jcmm.14356.
[15]	CHIARAVALLI M, SPRING A, AGOSTINI A, et al. Immunogenic cell death: An emerging target in gastrointestinal cancers[J]. Cells, 2022, 11( 19): 3033. DOI: 10.3390/cells11193033.
[16]	GALLUZZI L, KEPP O, HETT E, et al. Immunogenic cell death in cancer: Concept and therapeutic implications[J]. J Transl Med, 2023, 21( 1): 162. DOI: 10.1186/s12967-023-04017-6.
[17]	WANG XW, WU SW, LIU F, et al. An immunogenic cell death-related classification predicts prognosis and response to immunotherapy in head and neck squamous cell carcinoma[J]. Front Immunol, 2021, 12: 781466. DOI: 10.3389/fimmu.2021.781466.
[18]	GARG AD, DE RUYSSCHER D, AGOSTINIS P. Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis[J]. Oncoimmunology, 2015, 5( 2): e1069938. DOI: 10.1080/2162402X.2015.1069938.
[19]	BROWN ZJ, TSILIMIGRAS DI, RUFF SM, et al. Management of hepatocellular carcinoma: A review[J]. JAMA Surg, 2023, 158( 4): 410- 420. DOI: 10.1001/jamasurg.2022.7989.
[20]	TRICOLI L, NITURE S, CHIMEH U, et al. Role of microRNAs in the development of hepatocellular carcinoma and drug resistance[J]. Front Biosci(Landmark Ed), 2019, 24( 2): 382- 391. DOI: 10.2741/4724.
[21]	CEBALLOS MP, QUIROGA AD, PALMA NF. Role of sirtuins in hepatocellular carcinoma progression and multidrug resistance: Mechanistical and pharmacological perspectives[J]. Biochem Pharmacol, 2023, 212: 115573. DOI: 10.1016/j.bcp.2023.115573.
[22]	DEVAN AR, KUMAR AR, NAIR B, et al. Insights into an immunotherapeutic approach to combat multidrug resistance in hepatocellular carcinoma[J]. Pharmaceuticals(Basel), 2021, 14( 7): 656. DOI: 10.3390/ph14070656.
[23]	LI ZL, LAI XQ, FU SQ, et al. Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency[J]. Adv Sci(Weinh), 2022, 9( 22): e2201734. DOI: 10.1002/advs.202201734.
[24]	ZHANG SW, WANG J, KONG ZQ, et al. Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy[J]. Biomaterials, 2022, 282: 121433. DOI: 10.1016/j.biomaterials.2022.121433.
[25]	LIU GH, QIU YM, ZHANG P, et al. Immunogenic cell death enhances immunotherapy of diffuse intrinsic pontine glioma: From preclinical to clinical studies[J]. Pharmaceutics, 2022, 14( 9): 1762. DOI: 10.3390/pharmaceutics14091762.
[26]	SANSONE C, BRUNO A, PISCITELLI C, et al. Natural compounds of marine origin as inducers of immunogenic cell death(ICD): Potential role for cancer interception and therapy[J]. Cells, 2021, 10( 2): 231. DOI: 10.3390/cells10020231.

Relative Articles

[1]	Qiulu ZHANG, Zhuo LI, Congrong LIU, Limei GUO. Components of tumor stroma-immune microenvironment and their interactions in intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2025, 41(3): 594-600. doi: 10.12449/JCH250331
[2]	Xiaoqin ZHU, Na WEI, Yong XIAO, Baoping YU. Impact of hepatocellular carcinoma on the prognosis of patients with liver cirrhosis undergoing emergency endoscopic therapy due to esophagogastric variceal bleeding[J]. Journal of Clinical Hepatology, 2025, 41(2): 277-283. doi: 10.12449/JCH250213
[3]	Yuan DUAN, Ting ZHANG, Jing ZHANG, Guiwen GUAN, Jingzhou WANG, Xiangmei CHEN. Expression of AU-rich element RNA-binding factor 1 in hepatocellular carcinoma and its value in prognostic evaluation[J]. Journal of Clinical Hepatology, 2024, 40(9): 1833-1839. doi: 10.12449/JCH240918
[4]	Zheng SONG, Wei LUO, Xiujuan CHANG, Yongping YANG. Construction of a novel disulfidptosis-related prognostic model for patients with hepatocellular carcinoma based on bioinformatics analysis[J]. Journal of Clinical Hepatology, 2024, 40(9): 1822-1832. doi: 10.12449/JCH240917
[5]	Meng REN, Yi YANG, Ziming LI, Renqian ZHANG, Yufeng SHI, Junxiu TAO. Clinical features and prognosis of hepatocellular carcinoma： A single-center study of 850 cases[J]. Journal of Clinical Hepatology, 2024, 40(10): 2019-2026. doi: 10.12449/JCH241015
[6]	Xiaoli LIU, Qinwen TAN, Jian XU, Huanling CHEN, Jie YU, Lu LU, Mingkan DAI, Jingjing HUANG, Hongna HUANG, Dewen MAO. Effect of amino acid metabolic reprogramming on immune microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2024, 40(12): 2531-2537. doi: 10.12449/JCH241226
[7]	Xiaohua ZHANG, Ying FENG, Xianbo WANG. Role of the Hedgehog signaling pathway in hepatocellular carcinoma and its tumor microenvironment[J]. Journal of Clinical Hepatology, 2024, 40(4): 822-827. doi: 10.12449/JCH240429
[8]	Pinsheng HAN, Long YANG, Tao CUI, Yamin ZHANG. Role of tumor-associated macrophages in cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2023, 39(2): 469-473. doi: 10.3969/j.issn.1001-5256.2023.02.035
[9]	Peng WANG, Jiannan QIU, Zhongxia WANG, Junhua WU, Chunping JIANG. Research advances in tumor-associated macrophages in hepatocellular carcinoma microenvironment[J]. Journal of Clinical Hepatology, 2023, 39(5): 1212-1218. doi: 10.3969/j.issn.1001-5256.2023.05.033
[10]	Yanxin TIAN, Na LI, Lei GAO, Jia WU, Ying ZHU. Influence of the interaction between tumor microenvironment and liver cancer stem cells on the development and progression of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(3): 684-692. doi: 10.3969/j.issn.1001-5256.2023.03.032
[11]	Chaoran YANG, Sirou LI, Yuan LIU, Zhiyuan HOU, Yuan WANG, Jihong YANG. Role of non-coding RNA on immune cells in tumor microenvironment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(4): 961-967. doi: 10.3969/j.issn.1001-5256.2023.04.033
[12]	Fan YAO, Xin YIN. Regulatory effect of immune checkpoint TIGIT/CD155 on the immune microenvironment of primary liver cancer and its application prospects[J]. Journal of Clinical Hepatology, 2022, 38(11): 2632-2635. doi: 10.3969/j.issn.1001-5256.2022.11.039
[13]	Mingqiang ZHU, Youming DING. Current status of the research on microenvironment-targeting therapy and immunotherapy for liver cancer[J]. Journal of Clinical Hepatology, 2022, 38(8): 1913-1917. doi: 10.3969/j.issn.1001-5256.2022.08.038
[14]	Yiyi ZHANG, Min XU. Research advances in the mechanism of tumor microenvironment in pancreatic cancer and related targeted therapy[J]. Journal of Clinical Hepatology, 2022, 38(4): 965-968. doi: 10.3969/j.issn.1001-5256.2022.04.046
[15]	Shun CHEN, Jun WANG. Advances in tumor microenvironment and immunotherapy of Cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2022, 38(10): 2428-2432. doi: 10.3969/j.issn.1001-5256.2022.10.044
[16]	Xiao HU, Dewen MAO, Chengyu YA. Association between cancer-associated fibroblasts and liver cancer[J]. Journal of Clinical Hepatology, 2021, 37(2): 444-447. doi: 10.3969/j.issn.1001-5256.2021.02.041
[17]	Xueyan LI, Changjun WANG. Influence of hepatocellular carcinoma microenvironment on myeloid-derived suppressor cells[J]. Journal of Clinical Hepatology, 2021, 37(6): 1473-1476. doi: 10.3969/j.issn.1001-5256.2021.06.053
[18]	Feiyu ZHANG, Yakepu ADILA, Jinming ZHAO, Yanhang GAO. New advances in the treatment of pancreatic cancer by targeting tumor microenvironment[J]. Journal of Clinical Hepatology, 2021, 37(9): 2246-2248. doi: 10.3969/j.issn.1001-5256.2021.09.049
[19]	Hu Lei, Gao Li, Chen AiDong. Regulatory effect of tumor-associated neutrophils in the development and progression of liver cancer[J]. Journal of Clinical Hepatology, 2020, 36(9): 2100-2102. doi: 10.3969/j.issn.1001-5256.2020.09.043
[20]	Ma DeNing, Zhu XiaoDong, Tang ZhaoYou. Role of cancer- associated fibroblasts in growth and metastasis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(9): 865-868. doi: 10.3969/j.issn.1001-5256.2014.09.007

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(8) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (241) PDF downloads(26)

Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma

DOI: 10.12449/JCH241218

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Establishment of a risk model based on immunogenic cell death-related genes and its value in predicting the prognosis and tumor microenvironment characteristics of hepatocellular carcinoma

DOI: 10.12449/JCH241218

Abstract

References

Relative Articles

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content